Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.6K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

12
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
12
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

741
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
741
Disorders of Hemostasis01:24

Disorders of Hemostasis

982
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
982
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

8.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.2K
Introduction to Hemostasis01:05

Introduction to Hemostasis

8.2K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder.

Blood·2026
Same author

Destabilization of PF4-antigenic complexes in heparin-induced thrombocytopenia.

Blood·2025
Same author

Packaging of supplemented urokinase into alpha granules of in vitro-grown megakaryocytes for targeted nascent clot lysis.

Blood advances·2024
Same author

Treatment of thrombocytopenia and thrombosis in HIT in mice using deglycosylated KKO: a novel therapeutic?

Blood advances·2023
Same author

Vaccine-induced immune thrombotic thrombocytopenia.

Blood·2023
Same author

Human neutrophil peptides 1-3 protect the murine urinary tract from uropathogenic <i>Escherichia coli</i> challenge.

Proceedings of the National Academy of Sciences of the United States of America·2022
Same journal

Hyperlactataemia in lymphoma-associated haemophagocytic lymphohistiocytosis: Linked to monocytic glycolysis and adverse prognosis.

British journal of haematology·2026
Same journal

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

British journal of haematology·2026
Same journal

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.

British journal of haematology·2026
Same journal

Evaluating high-sensitivity troponin levels in people with sickle cell disease in the emergency department.

British journal of haematology·2026
Same journal

Methaemoglobinaemia: From pathophysiology to contemporary clinical management.

British journal of haematology·2026
Same journal

Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort.

British journal of haematology·2026
See all related articles

Related Experiment Video

Updated: Jul 16, 2025

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

19.8K

Pathogenesis of refractory ITP: Overview.

Douglas B Cines1,2

  • 1Department of Pathology and Laboratory Medicine, Perelman-University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.

British Journal of Haematology
|September 22, 2023
PubMed
Summary
This summary is machine-generated.

Refractory immune thrombocytopenia (ITP) lacks clear diagnostic criteria, complicating research. This review explores biological factors potentially underlying refractory ITP, guiding future diagnostic and therapeutic strategies.

Keywords:
B cellsT cellsantibodiesthrombocytopenia

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.8K
A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

7.7K

Related Experiment Videos

Last Updated: Jul 16, 2025

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

19.8K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.8K
A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

7.7K

Area of Science:

  • Hematology
  • Immunology

Background:

  • Refractory immune thrombocytopenia (rITP) affects patients unresponsive to standard treatments, increasing bleeding risks.
  • Current definitions of rITP vary, hindering research and clinical understanding.
  • The distinction between severe ITP and distinct pathogenic pathways in rITP remains unclear.

Purpose of the Study:

  • To review potential biological features associated with refractory immune thrombocytopenia (rITP).
  • To explore differences that may distinguish rITP from typical immune thrombocytopenia (ITP).
  • To identify potential biomarkers for anticipating or diagnosing rITP.

Main Methods:

  • Literature review of studies investigating biological factors in immune thrombocytopenia (ITP).
  • Analysis of genetic, epigenetic, immunological, and platelet-related factors.
  • Synthesis of findings related to T cell dysregulation, autoantibodies, complement activation, and platelet kinetics.

Main Results:

  • Potential associations with genetic/epigenetic factors, T cell/cytokine dysregulation, antibody characteristics, complement activation, and impaired platelet production/clearance were identified.
  • These factors may contribute to the refractory state in immune thrombocytopenia (ITP).
  • The review highlights heterogeneity in the definition and understanding of refractory disease.

Conclusions:

  • Understanding the specific pathogenic pathways in rITP is crucial.
  • Longitudinal studies with novel methodologies are needed to identify and monitor key biomarkers.
  • This research aims to improve diagnosis, monitoring, and treatment of refractory immune thrombocytopenia.